PDGFRB and Cowden disease: FDA-approved fidaxomicin-mediated inhibition of collagen expression and PDGFRβ activity and expression in CDS patient-derived fibroblasts and human and mouse intestinal tissues is clinically relevant for the precision treatment of intestinal strictures among CD patients.